Study of Palbociclib in MLL-rearranged Acute Leukemias

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia
Interventions
DRUG

Palbociclib

oral, once daily (125mg, 100mg or 75mg) for 21 days

Trial Locations (24)

12200

RECRUITING

Charité Campus Benjamin Franklin, Berlin

12351

RECRUITING

Vivantes Klinikum Neukölln, Berlin

13353

RECRUITING

Charité Campus Virchow-Klinikum, Berlin

15526

RECRUITING

Helios Klinikum Bad Saarow, Bad Saarow

20246

RECRUITING

Universitätsklinikum Hamburg-Eppendorf, Hamburg

24116

RECRUITING

Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel

24939

RECRUITING

Malteser Krankenhaus St. Franziskus-Hospital, Flensburg

26121

RECRUITING

Pius Hospital Oldenburg, Oldenburg

30625

RECRUITING

Medizinische Hochschule Hannover, Hanover

35392

RECRUITING

Universitätsklinikum Giessen, Giessen

36043

RECRUITING

MVZ Osthessen, Fulda

38114

RECRUITING

Städtisches Klinikum Braunschweig gGmbH, Braunschweig

39120

RECRUITING

Uni-Klinikum der Otto-von-Guericke-Universität, Magdeburg

40225

RECRUITING

Universitätsklinikum Düsseldorf, Düsseldorf

45239

RECRUITING

Kliniken Essen Süd, Ev. Krankenhaus Essen-Werden gGmbH, Essen

53105

RECRUITING

Universitätsklinikum Bonn, Bonn

55131

RECRUITING

Universitätsmedizin der Johannes Gutenberg-Universität, Mainz

66822

RECRUITING

Caritas-Krankenhaus Lebach, Lebach

69120

RECRUITING

Universitätsklinikum Heidelberg, Heidelberg

72076

RECRUITING

Medizinische Universitätsklinik Tübingen, Tübingen

76133

RECRUITING

Städtisches Klinikum Karlsruhe gGmbH, Karlsruhe

86156

RECRUITING

Klinikum Augsburg, Augsburg

89081

RECRUITING

University Hospital of Ulm, Ulm

791016

RECRUITING

Universitätsklinikum Freiburg, Freiburg im Breisgau

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

National Center for Tumor Diseases, Heidelberg

OTHER

lead

University of Ulm

OTHER

NCT02310243 - Study of Palbociclib in MLL-rearranged Acute Leukemias | Biotech Hunter | Biotech Hunter